Examining the impact of Medicaid-managed care home-based and community-based service (HCBS) alternatives to institutional care is critical given the recent rapid expansion of these models nationally.
H ome-based and community-based service (HCBS) alternatives to institutional care have been emphasized as cost-effective, patient-oriented approaches that allow Medicaid enrollees to receive long-term services and supports (LTSS) in their homes and communities. 1 In 2011, >3.2 million Medicaid beneficiaries received HCBS, accounting for almost half of Medicaid expenditures on LTSS. 1 There has been rapid growth in the use of managed care to provide LTSS through 1915 (b)/(c) managed care/HCBS waivers or 1115 demonstration waivers, increasing from 8 state Medicaid programs in 2004 to 18 programs in 2014. 2 However, little is known about the quality of care delivered through these programs. The Department of Health and Human Services Office of the Inspector General identified concerns with inconsistent monitoring of the quality of HCBS programs, noting that "the beneficiaries y are among Medicaid's most vulnerable, and the nature of these programs puts beneficiaries at risk for receiving inadequate care." 3 Although there is considerable research on the effect of Medicaid-managed care delivery for children, their parents and other lowincome beneficiaries, there is a paucity of information on the effects of managed care and HCBS waiver programs for adults with disabilities (AWD), which may be due to the relatively recent expansion of these programs or inconsistent and heterogeneous reporting of quality information. [4] [5] [6] Of the existing research, Burns 5 found that Medicaid AWD in mandatory managed care were more likely to wait to see a provider, report difficulty obtaining specialty care, and less likely to receive a flu shot compared with fee-for-service (FFS) enrollees; yet they were also more likely to report having a usual source of care. Coughlin et al 7 also found that Medicaid-managed care was positively associated with having a usual source of preventive care among AWD compared with FFS. Neither study focused specifically on AWD enrolled in HCBS waiver programs.
More than one third of AWD in Medicaid have 3 or more chronic conditions, and the chronic condition profile of AWD is different than for other Medicaid high-use groups. For example, AWD are more likely to have psychiatric illness, substance abuse, and developmental disability diagnoses compared with aged Medicaid enrollees. 8 The high rates of chronic disease comorbidity and differential chronic condition profile highlights the importance of understanding the impacts of HCBS on the quality of chronic disease care among Medicaid AWD. 8, 9 Ensuring the delivery of recommended care contributes to improved disease management and the ability to remain in a home setting.
The purpose of our study was to examine the effects of a large acute care and HCBS program delivered through managed care organizations in Texas Medicaid-the STAR+PLUS program-on the quality of chronic disease care for AWD. In 2012, Texas Medicaid enrollees accounted for one half of all enrollees nationally in Medicaid-managed care LTSS programs. 10 A primary focus of STAR+PLUS is to improve the quality of care for enrollees with disabilities through coordinated and comprehensive care. The program delivers acute and LTSS through a single system; employs service coordinators who develop individual care plans and assist enrollees in receiving needed care; and emphasizes HCBS alternatives to institutional care. 11 In addition, in a fully capitated health care delivery model like STAR+PLUS, evidence suggests that care which has the potential to reduce future visits, such as medications for chronic condition management, is provided more frequently compared with FFS payment. 12 Given this evidence and the key program objectives to provide more integrated and coordinated care compared with the preexisting FFS and primary care case management (PCCM) Medicaid program components, we hypothesized that the quality of care for chronic conditions would improve after STAR+PLUS enrollment and relative to a comparison group that remained enrolled in FFS or PCCM. To test this, we performed a series of longitudinal mixed-model analyses with a comparison group.
Our study offers several contributions to the literature. First, it focuses specifically on Medicaid AWD older than 65 years in contrast to the more frequently studied Medicare-Medicaid dual-eligible populations. [13] [14] [15] [16] Second, most research on HCBS has examined health care expenditures or access to care rather than specific quality indicators. 5, 17 Third, we study a program with mandatory enrollment, overcoming the limitation of potential selection bias in prior research on waiver programs with voluntary enrollment. Thus, our study extends existing knowledge by examining the effects of HCBS delivered through an integrated managed care program on the quality of care provided for common chronic conditions among Medicaid AWD.
METHODS

Overview
Currently, there are 13 STAR+PLUS service areas (SAs) that encompass all 254 counties in Texas. SAs are contiguous counties grouped together to organize health care delivery for Texas Medicaid. STAR+PLUS was phased-in over time by SA, and some individual SAs transitioned asynchronously (ie, subsets of counties within a SA transitioned in different years). STAR+PLUS was piloted in 1998 in the Harris SA (initially comprised of Harris County). The program expanded to 40 additional counties in January and February of 2007, comprising subsets of 4 SAs. The remainder of the counties in these 4 SAs, plus 6 additional SAs, transitioned in 2011 and 2012. On September 1, 2014, STAR+PLUS completed statewide expansion ( Fig. 1 ) (see Table, Supplemental Digital Content 1, http://links.lww.com/ MLR/A934 for a listing of county transitions). 18 Texas selected SAs for initial implementation based on the presence of a strong health care infrastructure to increase the likelihood of successful program implementation. The phased implementation allowed us to compare the quality of care enrollees received for a range of chronic conditions before and after their transition to STAR+PLUS and relative to enrollees who were phased-in later.
We used Texas Medicaid administrative data from January 2006 to December 2010 to estimate the treatment effect of the STAR+PLUS program on chronic care quality, focusing on the 2007 program expansions to allow for sufficient posttransition data for analysis. This timeframe includes a baseline year (2006), a transition year (2007), and 3 years posttransition for enrollees in the treatment counties. FFS and PCCM enrollees in counties that did not switch to STAR+PLUS during the study period served as the comparison group. We did not further distinguish between FFS and PCCM enrollees in our analyses based on existing research indicating few differences in access to care among adult Medicaid enrollees in general and those with disabilities in particular. 7, [19] [20] [21] In addition, postanalysis comparison of the control variables and baseline measure FIGURE 1. Map of Texas counties, with color indicating the date of STAR+PLUS implementation. For adults with disabilities, Medicaid was delivered in fee-for-service and primary care case management models before STAR+PLUS implementation.
Population and Data Sources
The study population included individuals of 21-64 years old who were enrolled during the study time period and qualified for Supplemental Security Income and Medicaid due to disability. Dual Medicare-Medicaid eligible were excluded because Medicare data were not available for those enrollees. Individuals older than 21 years were excluded because STAR+PLUS enrollment was voluntary for this group. We excluded enrollees in the 1998 Harris SA pilot because it was not possible to generate separate program effect estimates to compare mature versus newly implemented STAR+PLUS with only a single observational unit.
Person-level administrative enrollment and claims/encounter data provided by the Texas Health and Human Services Commission were used to obtain enrollees' age, sex, race/ethnicity, county, SA, monthly enrollment, and delivery model (STAR+PLUS or FFS/PCCM). Enrollment records were linked to claims data that included International Classification of Diseases (ICD-9-CM) diagnosis codes, Current Procedural Terminology codes, and National Drug Codes. These data were supplemented with county, Zip Code Tabulation Area, and census tract-level data from the Area Resource File, US Census Bureau, and US Department of Commerce to capture geographic contextual factors. The sample size varied for each outcome according to the eligibility inclusion criteria for each quality measure described below.
Outcome Variables
We used chronic care quality indicators from the National Committee for Quality Assurance (NCQA)'s Healthcare Effectiveness Data and Information Set (HEDIS): (1) use of appropriate medication for people with asthma; (2) medication management for people with asthma at the 75% level; (3) pharmacotherapy for chronic obstructive pulmonary disease (COPD) exacerbation; (4) cholesterol management for people with cardiovascular conditions; (5) persistence of b-blocker treatment after a heart attack; and (6) comprehensive diabetes care. These measures were selected because they reflect quality of care for the Agency for Health Care Research and Quality's "Priority Conditions" 22 and were suggested by the Centers for Medicare & Medicaid Services as initial health care quality core measures for adults in Medicaid. Strong performance on these indicators is linked to improved health outcomes. 23 We used NCQA-certified software (Quality Spectrum Insight v15.2011; Inovalon), applying 2012 HEDIS technical specifications to determine person-level compliance for each measure in each study year (see Table, Supplemental Digital Content 3, http://links.lww.com/MLR/A936 for measure definitions). 24 For COPD exacerbation pharmacotherapy, we calculated the average of the compliance rates for appropriate corticosteroid and bronchodilator dispensing. For diabetes care, we constructed a person-level composite measure used in prior research that averages the compliance rates of the subcomponents: annual hemoglobin A1c testing, eye examination, low-density lipoprotein cholesterol screening, and nephropathy screening. 25 For the remaining measures, person-level dichotomous indicators of compliance were created.
Predictor Variables
For each member-year, we computed our main predictor variable as the number of STAR+PLUS enrollment months (0-12) (see Text, Supplemental Digital Content 4, http://links.lww.com/MLR/A937 for more detail on the main predictor's definition and behavior). We also controlled for several person-level and contextual variables. 5, 26 First, for each outcome, person-level measure compliance in 2006 was used to control for baseline differences between the 2 studied groups. We constructed a variable to indicate if Z5 enrollees were residing at the same address to identify group living arrangements. We also used the 3M Clinical Risk Groups, which uses ICD-9-CM diagnosis codes from health care encounters for individuals enrolled Z6 months to assign enrollees to the following hierarchically defined health status categories: healthy, significant acute conditions (eg, chest pains), minor chronic conditions (eg, migraine), moderate chronic conditions (eg, asthma and diabetes), or major chronic conditions (eg, cystic fibrosis and cancer). 27 Less than 1% of individuals lacked sufficient enrollment history for classification and were excluded. Additional individual characteristics included age at baseline (y), sex, and race/ ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, other). Contextual geographic variables included the percentage of the population living in poverty in the enrollee's census tract (or Zip Code Tabulation Area if census tract was unavailable) and county-level median household income. Dummy variables for each year were controlled for secular trends. The full model included 2-, 3-, and 4-way predictor interactions and predictor interactions with time to test for time-varying treatment effects.
Model Specification
Although SAs represent administrative clustering and the approximate unit at which STAR+PLUS was implemented, there were too few units to have sufficient statistical power. In addition, some SAs were transitioned in phases. Accordingly, we selected an intermediate clustering unit (county), which provides sufficient power and accounts for potential nonindependence among enrollees. The county reasonably represents the context within which enrollees seek health care and captures administrative similarity of the care environment, such as available health care resources that impact health service use.
We employed a 2-stage, multilevel approach using general linear models. First, we computed person-level models separately for each year and outcome. Using individually adjusted averages and assuming unstructured correlations over time, we then built the second tier model for each outcome, spanning the postbaseline years (2007) (2008) (2009) (2010) . With these 6 full models, fixed-order backwards selection of predictor variables with a = 0.05 was used to arrive at the reduced models. Finding general agreement in terms retained between the models, we established 1 final reduced model form for consistency. R 2 statistics were then estimated. 28 Finally, we computed the least-squares-mean predicted compliance rates for the STAR+PLUS and FFS/ PCCM counties using group-specific covariate distributions. The difference between these estimates reflects the STAR+PLUS effect.
Our modeling approach is a mathematical generalization of a difference-in-difference (DD) approach. The standard DD model compares differences between 2 groups at 2 timepoints to isolate and test the presence of an effect, assumed to be a deviation from the baseline difference. In a design with >2 timepoints (eg, in our study with 4 postbaseline measurements), DD requires aggregation of the postperiod measurements as a single timepoint or computation of 4 separate DD models for each outcome. Our strategy models all postperiod measurements simultaneously, while accounting for the covariance of repeated measurements, thus increasing power relative to the standard DD approaches. This generalized approach also relaxes the DD parallel trend assumption requiring similar rates of growth between groups by allowing for differing slopes (see Text, Supplemental Digital Content 5, http://links.lww.com/MLR/ A938 for more technical detail). Analyses were performed using SAS 9.3 (SAS Institute Inc., Cary, NC). Table 1 provides summary demographic and health status information for Texas Medicaid AWD meeting the inclusion criteria, stratified by time period and delivery system (STAR+PLUS counties or FFS/PCCM counties). Eighty percent of enrollees were assigned to the most severe health status category. Two thirds were younger than 50 years, and a similar fraction was female. Reflecting Texas' diversity, >50% of the sample was Hispanic or non-Hispanic black. Over half lived in census tracts designated as impoverished or extremely impoverished.
RESULTS
All descriptive statistics were stable over the study period. However, enrollees residing in STAR+PLUS counties were more likely to be Hispanic and less likely to be non-Hispanic black or non-Hispanic white compared with those in FFS/PCCM counties. STAR+PLUS enrollees also resided in areas with slightly lower levels of poverty and higher median household income. Distributions of age, sex, and health status were similar. Table 3 provides unadjusted measure adherence rates by delivery system and time period. Measure adherence was similar between groups at baseline. However, baseline adherence rates varied widely between measures. For example, approximately 80% of enrollees with persistent asthma were dispensed at least 1 asthma controller medication, whereas <50% of those enrollees remained on the medication for the majority of the baseline year. In 2006, members discharged with COPD exacerbation received sustained bronchodilator or systemic corticosteroid 55% of time. Members were given long-term b-blocker therapy for approximately 50% of discharges after a heart attack.
Two of the 6 measures demonstrated sizable pre-post improvements in STAR+PLUS, but not in FFS/PCCM. bblocker treatment after a heart attack increased from 51% in the baseline year to 74% in the posttransition period for STAR+ PLUS enrollees; whereas rates for FFS/PCCM enrollees decreased from 53% to 45%. Similarly, the percentage of STAR+PLUS enrollees who received pharmacotherapy following a hospitalization or emergency department visit for COPD increased from 56% to 82%, whereas rates for FFS/PCCM enrollees remained stable at 58%. Little change *In the postbaseline period, data from 4 years were available; therefore, the range of enrollees/counties included in the analytic sample across these 4 years is given. between the pre-post periods was observed for the remaining measures (diabetes, asthma, and cholesterol management). Table 4 provides fit statistics and model-based estimates of the predicted means between groups for the final reduced models. R 2 statistics ranged from 0.166 to 0.517, indicating fair to good model fit. Our model did not converge for the diabetes outcome, and so although the point estimates for this measure are reliable, the SEs and model fit are undetermined. Also note that the effect of treatment was stable across time (ie, there was no interaction between time and the STAR+PLUS program variable). Correspondingly, all model-based estimates reflect the predicted county-level average effects of STAR+PLUS implementation on measure adherence across the 4 postimplementation years.
The model-based estimates, which were adjusted for control variables, administrative clustering, and correlation between outcomes over time, align closely with the unadjusted results. In STAR+PLUS counties, 28.5% (95% confidence interval, 21.6%-35.4%) more enrollees received appropriate medication following COPD exacerbation compared with FFS/PCCM counties. In addition, receipt of b-blocker following heart attack discharge demonstrated improvement of 32.0% (95% confidence interval, 6.8%-57.2%) in the STAR+PLUS counties relative to the FFS/ PCCM counties. We did not find statistically significant differences for the remaining measures (see Table, 
DISCUSSION
Measuring the impact of Medicaid-managed care HCBS waiver programs is critical given rapid expansion of these models nationally. In this study, we examined the ef-fect of the Texas STAR+PLUS HCBS waiver program on the quality of chronic disease care for Medicaid AWD. Our results demonstrate large and sustained improvements in care following both heart attack and COPD exacerbation. However, differences were not observed in the quality of ambulatory care for diabetics or asthmatics, or for cholesterol screening for those with cardiovascular conditions. Further research is necessary to identify the pathways through which the observed improvements were achieved and the reasons why improvements were not seen in all the measures. However, it is worth noting that the 2 measures for which we found significant improvements, persistence of bblockers after a heart attack and pharmacotherapy for COPD exacerbation, focus on care processes linked to an acute event. Thus, it may be that managed care quality improvement protocols were more readily implemented in the context of an acute event. For example, prior authorization is sought during inpatient admissions concomitant with an acute event, thereby providing care-coordinators a near realtime opportunity to influence care. In contrast, difficulty with patient follow-up for the remaining measures may be a particularly important factor contributing to the lack of significant findings. The immediacy of costs of poor quality may also be an important motivator for these differences. For example, with the acutely linked care examined here, the costs of poor quality care are realized quickly in readmissions and emergency department visits, whereas the consequences of inadequate ambulatory diabetes care or lipid screening occur over longer time spans.
Our study has several strengths. First, the study was conducted in Texas, which has the second largest Medicaid program in the United States. The population in STAR+ PLUS is racially and ethnically diverse providing greater insight into the effects of a comprehensive HCBS program in a broad population. Second, this study is based on a natural experiment in which STAR+PLUS was mandatorily phased into different counties for Medicaid AWD, providing a high level of internal and ecological validity. As in all observational studies, there is possibility of residual confounding. However, bias introduced by nonrandom phase-in is largely attenuated through the study design, which included the baseline value of the outcome and modeled separate slopes for each study group. To threaten internal validity, an external influence would have (1) needed to mirror the implementation of STAR+PLUS, that is occurring only in the transitioned counties and during the same period under study in this analysis; and (2) not been closely correlated to the repeatedly measured contextual and individual control variables. 29 Our study also has limitations that should be considered when interpreting the results. First, the NCQA-certified software that we used to calculate the chronic care measures uses health care claims and encounter data, the quality of which may be affected by coding practices. As part of ongoing quality of care evaluation for the Texas Medicaid program, we conduct encounter data validation of the administrative claims data against medical records following Centers for Medicare & Medicaid Services external quality review protocols. 30 A random sample of >1100 medical records for STAR+PLUS are reviewed annually by certified medical record coders and compared with claims/encounter data fields (eg, ICD-9-CM codes, Current Procedural Terminology codes, date of service, place of service, and rendering provider) with >92% agreement, lending confidence in the data quality. Second, Medicaid-managed care HCBS waiver programs implemented through managed care organizations differ throughout the United States. Therefore, it is possible that the findings in our study are not generalizable to other Medicaid programs. Even so, the pattern of improved care linked to specific acute events, versus that delivered in routine care settings is seen frequently. 31 Further, information about the structure of the STAR+PLUS program is available, and policymakers and health care providers can examine the extent to which the program design characteristics are similar to existing or proposed programs. 11, 32, 33 Given variability in HCBS programs, future research should examine specific types of HCBS received and their association with quality of care. It also would be prudent to explore potential heterogeneity in program implementation and see if this heterogeneity leads to differences in quality improvements between health plans. Finally, this study examined process of care measures; future work should examine the extent to which these findings translate into improved health outcomes.
In summary, in 1 large Medicaid-managed care HCBS program, the quality of chronic disease care linked to acute events improved while that provided during routine encounters appeared unaffected. Additional research is needed to further evaluate and refine care for this vulnerable population.
